Home / Middle East Pharmaceutical Industries Co. / 2025 Annual Results

Middle East Pharmaceutical Industries Co. 2025 Annual Results

Revenue

SAR 460M

Net Profit

SAR 97M

EPS

SAR 4.85

Operating Cash Flow

SAR 89M

Middle East Pharmaceutical Industries Co. (4016) reported full year 2025 revenue of SAR 460M, up 16.9% from SAR 394M in 2024. Net profit came in at SAR 97M, up 21.5% year on year. Earnings per share were SAR 4.85. The company generated SAR 89M in operating cash flow. All figures sourced from CMA-mandated XBRL filings on the Saudi Exchange, processed by Sahm Screener.

Earnings Quality

Of every SAR 1.00 in reported net profit, SAR 0.91 arrived as operating cash flow — indicating High quality earnings with a cash conversion ratio of 0.91.

Key Financial Metrics

Metric	2025	2024
Revenue	SAR 460M	SAR 394M
Net Profit	SAR 97M	SAR 80M
Net Margin	21.1%	20.3%
ROE	2.3%	21.7%
EPS	SAR 4.85	SAR 3.99
Total Assets	SAR 600M	SAR 527M
Total Equity	SAR 4.16B	SAR 368M
Total Liabilities	SAR 183M	SAR 159M
Operating Cash Flow	SAR 89M	SAR 35M

Year on Year Comparison

Revenue increased by 16.9% compared to 2024. Net profit increased by 21.5%. Both revenue and profit grew — indicating expanding business.

View full company profile →

View all years:

2025 2024 2023

Financial data sourced from CMA-mandated XBRL filings published on the Saudi Exchange (Tadawul). Data processed and structured by Sahm Screener (sahmscreener.com). Updated nightly. Last updated: 2026-03-10.